Myomo® Announces New Sales and Service Agreement for Chile

Tecnoplanta Expands its Portfolio with MyoPro®

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable
medical robotics company that offers increased functionality for those
suffering from neurological disorders and upper limb paralysis, today
announced that it has signed an agreement with Tecnoplanta Orthopedic
Laboratory with the goal of offering MyoPro in Chile.

With over 20 years of operation, Tecnoplanta Orthopedic Laboratory is
dedicated to providing services in both orthoses and prostheses for
people who have suffered strokes, amputations or musculoskeletal
malformations, providing patients with high quality products of advanced
technology. Tecnoplanta serves patients in Chile and across Latin

Mario Campos, Tecnoplanta Chief Product Officer, Chief Innovation
Officer, Chief Orthotics and Prosthetics Technician explains, “Our
vision is to be an orthopedic laboratory recognized by health
organizations throughout Chile as providing a high quality and efficient
service responding to the demands of a globalized, changing and
competitive world. Our mission is to deliver high quality care to our
patients, committed from the beginning with their recovery process
providing high-tech supplies, backed by large world-renowned companies
in the field of technical orthopedics, such as Myomo.”

Paul R. Gudonis, Chairman and CEO of Myomo, said, “Since individuals
from around the world are seeking a MyoPro for their paralyzed arms,
this agreement with Tecnoplanta enables Myomo to assist patients in
South America, supplementing our existing international reach in Canada
and Europe. Myomo and Tecnoplanta are ideal partners, both of us
committed to excellence in technology and patient care.”

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers expanded
mobility for those suffering from neurological disorders and upper limb
paralysis. Myomo develops and markets the MyoPro product line. MyoPro is
a powered upper limb orthosis designed to support the arm and restore
function to the weakened or paralyzed arms of patients suffering from
CVA stroke, brachial plexus injury, traumatic brain or spinal cord
injury, ALS or other neuromuscular disease or injury. It is currently
the only marketed device that, sensing a patient’s own EMG signals
through non-invasive sensors on the arm, can restore an individual’s
ability to perform activities of daily living, including feeding
themselves, carrying objects and doing household tasks. Many are able to
return to work, live independently and reduce their cost of care. Myomo
is headquartered in Cambridge, Massachusetts, with sales and clinical
professionals across the U.S. and representatives internationally. For
more information, please visit

Forward Looking Statements
This press release contains
forward-looking statements regarding the Company’s future business
expectations which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, our plans for offering our
MyoPro product in Chile, expansion of our business to Latin America and
beyond. These forward-looking statements are only predictions and may
differ materially from actual results due to a variety of factors. Our
actual results could differ materially from those anticipated in these
forward looking statements for many reasons, including, without
limitation, risks related to regulatory approval and market acceptance
of our products, our ability to secure and maintain reimbursement for
our products, our ability to obtain additional funding to sustain and
grow our business, and the other risk factors contained in our filings
made with the Securities and Exchange Commission. More information about
factors that potentially could affect Myomo’s business and financial
results is included in Myomo’s filings with the Securities and Exchange
Commission. The Company cautions readers not to place undue reliance on
any such forward-looking statements, which speak only as of the date
made. The Company disclaims any obligation subsequently to revise any
forward-looking statements to reflect events or circumstances after the
date of such statements or to reflect the occurrence of anticipated or
unanticipated events.


Investor Relations:
Vivian Cervantes
PCG Advisory


Sarah Karr
Matter Communications